EGFR and adenocarcinoma: In this study, overall EGFR mutations and subtypes other than exon 18 G719 X and exon 21 L861Q mutations were more frequent in women, non-smokers, and patients with adenocarcinoma, which is consistent with previous findings (Melosky et al., 2022; Li et al., 2020; Gao et al., 2020).